Boehringer Ingelheim, Roche Partnering on New Class of Bowel Disease Therapies

Boehringer Ingelheim, Roche Partnering on New Class of Bowel Disease Therapies
Boehringer Ingelheim and Roche are teaming up to develop a new class of inflammatory bowel diseases treatments. The partners will be focusing on therapies based on an innovative approach called Locked Nucleic Acid oligonucleotide technology. Under their agreement, the companies will share the cost of developing and marketing treatments. “The opportunity to work closely with the experts at

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *